Blue Cross Blue Shield Iowa becaplermin PRP Coverage Update | OpenPayer
ModifiedBlue Cross Blue Shield - IowaPolicy N/A
Recombinant PDGF (becaplermin) and Platelet-Rich Plasma (PRP) for wound healing and non-orthopedic indications
This policy governs clinical coverage determinations for becaplermin (recombinant PDGF) and autologous platelet-rich plasma (PRP) for wound management and other non-orthopedic indications for Blue Cross Blue Shield - Iowa members.
Policy Summary
PayerBlue Cross Blue Shield - Iowa
PolicyRecombinant PDGF (becaplermin) and Platelet-Rich Plasma (PRP) for wound healing and non-orthopedic indications
Policy CodePolicy N/A
Change TypeAnnual review with policy revision (March 2026)
Effective DateNov 1, 2019
Next Review DateN/A
Key ActionDocument that patients meet becaplermin candidate criteria (adequate TcPO2, full-thickness ulcer, participation in wound management) before use.
Policy was revised during the March 2026 annual review.
Review Date updated to March 2026 and policy revised March 2026.
Approvedapproved PDGF indications
InvestigationalPRP status
1997Regranex FDA year
Mar 2026evidence search through
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Black boxsafety signal
Annualpolicy review frequency
Coverage Criteria: Becaplermin (recombinant PDGF) and PRP
Covered when ALL of the following apply for the specified ulcer type
Diabetic neuropathic ulcers: Neuropathic diabetic ulcers extending into the subcutaneous tissue; adequate tissue oxygenation (TcPO2 >= 30 mm Hg); participation in a wound management program including sharp debridement, pressure relief/non-weight bearing, and infection control.see thresholds
Product used as adjunct to standard care; typical application once daily up to 20 weeks or until healed.
Pressure ulcers: Full-thickness pressure ulcer (stage III or IV) extending into subcutaneous tissue; ulcer in location that can be offloaded for duration of treatment; albumin >2.5 dL; total lymphocyte count >1000/μL; normal vitamins A and C; participation in a wound management program.see thresholds
Used as adjunct; application may be performed by patient at home.
Recombinant PDGF — Investigational Indications
Not covered because evidence is insufficient
Other recombinant PDGF uses: Ischemic ulcers; venous stasis ulcers; ulcers not extending through dermis into subcutaneous tissue; other applications not listed as medically necessary.
Evidence insufficient to determine improvement in net health outcome.
Platelet-Rich Plasma (PRP) — Investigational
PRP is considered investigational for acute or chronic wounds and multiple non-orthopedic indications
Wound care: PRP for acute surgical or traumatic wounds, chronic nonhealing ulcers (including diabetic, venous, pressure ulcers) — evidence is heterogeneous and insufficient to conclude consistent improvement in net health outcomes.
Meta-analyses and systematic reviews report mixed results with risk of bias and imprecision.
Non-orthopedic indications: PRP injections for alopecia areata/androgenetic alopecia, cerebral palsy, Crohn's disease-related perianal fistula, thin endometrium for infertility, urethral stricture, vitiligo — considered investigational due to insufficient and heterogeneous evidence.
Studies lack standardized PRP protocols and have methodological limitations.
Recombinant PDGF for diabetic lower-extremity ulcers (covered_with_criteria)
Evidence supports use of recombinant PDGF for diabetic lower-extremity ulcers when all study-like conditions are met:
Diabetic lower-extremity ulcer criteria: Patient has a diabetic lower-extremity ulcer; treatment is adjunctive to standard wound care; adequate tissue perfusion and monitoring with follow-up (typical interest ~20 weeks); outcomes monitored (complete healing, QOL, morbid events).follow-up ~20 weeks
RCTs and systematic reviews demonstrated improved complete healing rates; real-world retrospective data support higher healing and lower amputation rates when used in appropriate candidates.
Recombinant PDGF for pressure ulcers (covered_with_criteria)
Evidence supports use of recombinant PDGF for pressure ulcers under trial-like conditions:
Pressure ulcer criteria: Patient has a full-thickness pressure ulcer located where pressure can be offloaded during treatment; standard wound care is provided; treatment selection aligns with RCT inclusion criteria (full-thickness ulcers, offloadable location).not specified
A multicenter double-blind RCT showed improved healing with once-daily dosages; offloading and patient selection were important trial conditions.
Evidence summaries by indication
Evidence findings relevant to coverage decisions by indication:
Pressure ulcers: RCT(s) reported that once-daily becaplermin (0.01% or 0.03%) improved incidence of complete healing compared with placebo; no added benefit above 0.01%; twice-daily 0.01% did not improve outcomes in one trial.
Rees et al RCT showing benefit for certain dosing and offloadable ulcer locations.
Venous stasis leg ulcers: A multicenter, double-blind RCT showed no significant difference between becaplermin and control hydrogel for closure rates, ulcer area change, pain, or QOL at 8 and 12 weeks.
Evidence does not demonstrate benefit for venous leg ulcers.
Acute surgical/traumatic wounds and fingertip injuries: Nonrandomized controlled trials and a small prospective trial of fingertip injuries reported faster healing and faster return to work versus surgical reconstruction but were limited by small size and potential bias.
Promising but insufficient evidence for routine coverage in these indications.
Evidence summary and applicability
Summary of evidence findings from systematic reviews and meta-analyses
Evidence-supported effects: Multiple meta-analyses found PRP versus standard care modestly increases complete wound closure and shortens time to healing in diabetic foot ulcers; some analyses also reported reduced infection or amputation in pooled data, though quality and heterogeneity vary.
See Li 2019; AHRQ 2020; Deng 2023; Platini 2024; Hu 2025; Tian 2025 summaries.
Limitations affecting generalizability: Trials have high or unclear risk of bias, small sample sizes, short follow-up, poor reporting of PRP formulation and co-interventions (offloading, wound care), and underrepresentation of older adults; these limitations reduce certainty for outcomes beyond wound closure.
AHRQ 2020 and multiple reviews note these limitations.
Potential coverage with documentation-based criteria
Coverage reasonable when ALL of the following are documented:
Core requirements: 1) Wound diagnosis and etiology documented (diabetic foot ulcer, venous ulcer, pressure ulcer, or other chronic wound); 2) Evidence wound is chronic or nonhealing despite prior standard care (duration and prior therapies documented); 3) Baseline wound measurements recorded (area/volume) and planned outcome measures; 4) PRP treatment plan specified (preparation method, dosing/frequency, route, adjunct therapies such as offloading or compression); 5) Monitoring and follow-up plan for healing, infection, and adverse events.
Derived from trial inclusion criteria and concerns about heterogeneity and reporting in the literature.
Situations with insufficient evidence
Not recommended or lower confidence when ANY of the following apply:
Low-certainty or not supported: 1) Indication is acute surgical or traumatic wound without supportive high-quality RCT evidence specific to that setting; 2) Use for chronic wound types where meta-analyses show no consistent benefit in complete wound closure (for example, some venous ulcer analyses); 3) Use when key outcomes (complete healing, recurrence, amputation, QoL) are not reported or follow-up is insufficient to assess long-term efficacy.
Reflects summary statements and AHRQ findings about imprecision and bias.
Evidence synthesis by indication
Summary of clinical findings (not prescriptive criteria):
Aortic arch repair: One double-blind RCT (n=80) reported reduced perioperative transfusion and shorter hospital stay with PRP, but corroboration is needed.
Zhou et al 2015; limited corroboration needed.
Sternotomy wounds: Observational series and a meta-analysis reported lower sternal wound infection rates with PRP, but heterogeneity of PRP preparations and study quality limit interpretation; RCTs are needed.
Serraino et al and Zhu et al summaries.
Otolaryngology and other surgical wounds: Mixed RCT results across tonsillectomy, cleft palate repair, pilonidal surgery, and skin graft donor sites; some RCTs report shorter healing times but limitations include small samples and variable outcome definitions.
Mohamadi et al, Kazakos et al, and related trials show variable findings.
Evidence summaries by indication
Evidence and outcomes reported by indication
Androgenetic alopecia (AGA): Multiple small RCTs and systematic reviews/meta-analyses report increases in terminal hair count and thickness with PRP versus control but studies are heterogeneous, small, and use varied preparation and protocols; authors call for larger, standardized RCTs.
Evidence insufficient for routine adoption.
Alopecia areata (AA): Overall evidence is low quality and inconsistent; small RCTs and pilot studies show mixed results.
Further large trials needed.
Vitiligo: Systematic reviews report some studies showing improved repigmentation with PRP (often combined with other therapies) but trials are heterogeneous and at high risk of bias.
Well-designed comparative trials with standardized outcomes are recommended.
General stance for miscellaneous PRP indications
Coverage considerations based on current evidence and guidelines
General coverage requirement: PRP for miscellaneous indications (vitiligo, cerebral palsy, Crohn's-related perianal fistula, urethral stricture, thin endometrium, alopecia) should be considered investigational or conditional because evidence is limited, heterogeneous, and lacks standardized preparation protocols.
Guideline positions vary: some societies advise against or express uncertainty about PRP for diabetic foot ulcers and other indications.
Thin endometrium
Indication-specific evidence snapshot
Thin endometrium (intrauterine PRP): A 2024 meta-analysis of 8 RCTs (678 patients) showed improved endometrial thickness, clinical pregnancy rate, live birth rate, and implantation rate with intrauterine PRP versus control; trials varied in PRP preparation and quality, limiting definitive coverage endorsement.
No reported complications in included studies but larger rigorous trials are needed.
Perianal fistula, urethral stricture, and other case evidence
Pilot/case-series evidence
Perianal Crohn's fistula, urethral stricture, mucosal flap adjuncts, other case reports: Small pilot studies and case series report mixed healing outcomes (e.g., 33%–40% complete healing at 24–48 weeks in a 29-patient PRP intrafistular Crohn study; 70% healing at 1 year when PRP combined with mucosal advancement flap in 10 patients) but are limited by size, design, and inconsistent adverse event reporting; insufficient for routine coverage.
Systematic reviews suggest adjuncts such as mitomycin C have stronger evidence for urethral stricture than PRP.
Use of platelet-rich plasma (PRP) is designated investigational for the treatment of acute or chronic wounds and for the non-orthopedic indications listed in this policy. The policy identifies recombinant PDGF (becaplermin) as medically necessary only for specified diabetic neuropathic and certain pressure ulcers when all selection criteria are met; all other uses of PRP or recombinant PDGF not meeting those criteria are considered investigational because the evidence is insufficient to demonstrate improvement in net health outcomes.
Clinical trials that supported benefit for topical growth-factor therapy (becaplermin) required patients with ulcers that could be offloaded during treatment and otherwise met trial inclusion criteria. Patients with pressure ulcers who cannot be offloaded at the treated anatomic site were effectively excluded from key randomized trials and therefore may not be appropriate candidates for these therapies without clear documentation that trial-like selection and adjunctive wound care (sharp debridement, infection control, pressure relief) have been provided.
Evidence for PRP and for recombinant PDGF in venous stasis (venous leg) ulcers does not demonstrate consistent benefit. A multicenter double-blind RCT of becaplermin in venous leg ulcers showed no significant difference versus control, and systematic reviews/meta-analyses of PRP in venous ulcers have not shown reliable improvements in closure, recurrence, infection, or quality-of-life outcomes; these findings support exclusion or a noncovered stance for venous stasis ulcers absent compelling documentation.
Systematic reviews that pooled heterogeneous wound types without stratifying by wound etiology or key cointerventions limit applicability to specific clinical scenarios. Because pooled analyses combining diverse ulcer types and variable cointerventions obscure condition-specific effects, such heterogeneous reviews are of limited use for determining coverage for a particular wound type.
For many acute or chronic wound indications, the body of evidence is insufficient to conclude PRP improves net health outcomes. Meta-analyses indicate modest increases in complete wound closure for some diabetic foot ulcer trials, but risk of bias, imprecision, short follow-up, and inconsistent reporting of important outcomes mean routine coverage for PRP in these settings is not supported by current evidence.
Across multiple conditions studied, trials frequently show small benefits or no difference versus standard care for outcomes of clinical interest (complete closure, infection, amputation, quality of life). Where meta-analyses report modest improvements in closure or time to healing, the clinical significance is limited by methodological shortcomings and heterogeneity among trials.
There is currently no consensus standard for PRP preparation, platelet concentration, activation method, dosing frequency, or mode of administration. Variability across commercially available PRP systems and protocols contributes to heterogeneous study results and limits generalization of findings to routine clinical practice.
NICE guidance (2019) advises that autologous platelet-rich plasma gel and platelet-derived growth factors should not be offered for the treatment of diabetic foot ulcers, reflecting guideline-level caution about routine PRP use for this indication.
Note that HCPCS code G0465 is described for autologous PRP for diabetic chronic wounds only when an FDA-cleared device for this indication is used; correct device-specific coding is required when claiming services under this descriptor.
Summary position: PRP is investigational for both acute and chronic wounds, including surgical wounds and nonhealing ulcers, and for the non-orthopedic indications listed in this policy. The available evidence—systematic reviews, RCTs, and case series—is heterogeneous and of variable quality, and does not reliably demonstrate net health benefit for these uses.
Because PRP systems differ in processing steps and yield variable platelet and protein concentrations, evidence from trials using a specific PRP method cannot be assumed to apply to other uncharacterized systems. Coverage decisions should therefore consider whether the proposed PRP preparation matches the methods used in supporting trials.
A randomized, multicenter double-blind trial of becaplermin for venous leg ulcers found no difference in closure rates or other outcomes versus control hydrogel, a result supporting exclusion of venous stasis ulcers from medically necessary indications for recombinant PDGF.
Although several meta-analyses report modest increases in closure or shorter time to healing for diabetic foot ulcers with PRP, limitations in study quality, small sample sizes, and inconsistent reporting prevent firm conclusions about clinically meaningful benefits beyond these modest effects.
Routine use of PRP in wound care lacks consistent, high-quality evidence across important outcomes. Small, heterogeneous trials with high or unclear risk of bias and variable PRP preparations make it inappropriate to endorse PRP as a standard therapy outside of well-documented trial-like use or research settings.
Many proposed uses of PRP are supported only by single-case reports, small uncontrolled case series, or pilot studies. These limited data sources are inadequate to support routine coverage or clinical adoption for those indications.
Several miscellaneous indications for PRP (for example, cerebral palsy, urethral stricture adjuncts, perianal Crohn’s disease, and thin endometrium) are not established as effective due to lack of standardized preparation protocols, small heterogeneous studies, and insufficient randomized comparative evidence; therefore these indications are considered investigational pending rigorous RCTs.
Coding and Billing
Codes table referencedmixed
No codes listed
Covered CPT CodesCPTCovered
0232T
Injection(s). platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed
Autologous platelet rich plasma or other blood-derived product for non- diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration and dressings, per treatment.
Covered HCPCS Codes - diabetic woundsHCPCSCovered
G0465
Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
Supply HCPCSHCPCSCovered
P9020
Platelet rich plasma, each unit.
Miscellaneous codes (product-specific)HCPCS
S0157
Becaplermin gel 0.01%, 0.5 gm.
Miscellaneous codes (growth factors)HCPCS
S9055
Procuren or other growth factor preparation to promote wound healing.
Transcutaneous partial pressure of oxygen (TcPO2) — clinical threshold
TcPO2 thresholdTranscutaneous partial pressure of oxygen (TcPO2) ≥ 30 mm Hg measured on the foot dorsum or at the ulcer margin
Measurement siteFoot dorsum or at the margin of the ulcer
PurposeDemonstrates adequate tissue oxygenation required for becaplermin candidacy
Albumin concentration — clinical threshold
Albumin thresholdSerum albumin concentration > 2.5 dL
Prior Authorization, Documentation, and Clinical Steps
Prior Authorization
Prior Approval and Coding
Not applicable. Prior approval is not required through a separate prior-approval program; however, prior authorization is recommended in situations described below so the medical record documents that the patient meets trial-like selection criteria and required documentation elements.
Prior approval note: Prior approval is not applicable; member records must demonstrate that becaplermin candidate selection criteria are met.
Code usage for authorization: When requesting any authorization or submitting claims, report exact CPT/HCPCS/Revenue and ICD-10 diagnosis codes for the service (see coding block).
Prior Authorization
Prior Authorization to Confirm Trial-Like Selection
For therapies with limited, heterogeneous evidence (notably PRP) or therapies with known safety signals (becaplermin/Regranex), prior authorization should be used to confirm that patient selection mirrors evidence-based trial criteria and that the treatment is being used as an adjunct to standard wound management.
Prior authorization to confirm trial-like selection: request documentation that the patient meets the relevant trial-like inclusion criteria (wound type, depth/stage, ability to offload, duration, and prior standard wound care).
Background and Rationale
Background: Recombinant platelet-derived growth factor (becaplermin) and autologous platelet-rich plasma (PRP) have both been investigated as adjuncts to standard wound care across a range of wound types, including diabetic neuropathic ulcers, pressure ulcers, venous stasis ulcers, acute surgical and traumatic wounds, fingertip injuries, and various non-orthopedic conditions. Becaplermin has randomized-trial evidence supporting use for selected diabetic neuropathic and certain pressure ulcers when trial-like patient selection and adjunctive care are provided; PRP evidence is heterogeneous and mixed, leading to an investigational stance for most wound and non-orthopedic indications.
Safety considerations: Long-term safety studies and insurance-database analyses found more cancer deaths among patients who used Regranex, particularly those with 3 or more prescriptions; FDA added a black box warning. Consider risk-benefit before multiple-course use.>=3 prescriptions associated with increased cancer deaths
May affect authorization for repeated use.
Traumatic and burn wounds: Meta-analyses of RCTs for burn wounds show improved healing rates and shorter time to healing with PRP, but heterogeneity, risk of bias, and short follow-up temper confidence.
Huang et al and Imam et al meta-analyses summarized.
Perianal Crohn's disease (perianal fistula):
Observational studies and small case series report moderate efficacy for local PRP injections with lower complete healing rates (~38.5% pooled) compared with combination therapies; findings are heterogeneous and limited by small samples.
Pilot studies combining PRP with surgical flap reported higher healing in small series but require validation.
Other/experimental uses: Uses such as cerebral palsy, urethral stricture adjuncts, and other case-report level evidence are limited and insufficient to support routine coverage without RCT validation.
Case reports and small uncontrolled studies predominate.
Context
Required for pressure-ulcer candidates for becaplermin
RoleNutritional marker used to support candidacy and wound-healing potential
Total lymphocyte count — clinical threshold
Total lymphocyte count thresholdTotal lymphocyte count > 1000/μL
ContextRequired for pressure-ulcer candidates for becaplermin
InterpretationIndicator of immune/nutritional status relevant to wound-healing candidacy
Place of Service — Inpatient, Outpatient, Home
Place of service - inpatientInpatient
Place of service - outpatientOutpatient
Place of service - homeHome (applications may be performed by patient at home)
Adjunctive therapy requirement: Becaplermin must be used as an adjunct to standard wound management; document participation in a wound management program including sharp debridement, offloading/non-weight bearing, and infection control.
Adjunct to standard care: Recombinant PDGF (becaplermin) is considered adjunctive or after failure of standard wound care comparators used in trials.
Prior Authorization
Surgical Uses of PRP
Surgical and perioperative uses of PRP have mixed and limited RCT evidence. For surgical applications (e.g., sternotomy, aortic arch repair, mucosal advancement flap with PRP), prior authorization is advisable to ensure indication appropriateness and detailed surgical documentation.
Prior authorization advisable for surgical PRP use: Request operative report, indication for PRP, site-specific rationale, and comparator or adjunctive therapies used.
Trial-based documentation recommended: When applying PRP in procedures studied in trials, request documentation that follows trial protocols (timing, volume, preparation, and specific application technique).
Prior Authorization
Perianal Crohn's Disease and PRP
Because evidence is limited and mostly from small observational studies and heterogeneous protocols, prior authorization is suggested for PRP use in perianal Crohn's disease to document indications, concurrent biologic therapy status, and detailed procedural technique.
PRP for perianal Crohn's disease — authorization suggested: Request documentation of fistula characteristics, prior fistula therapies, seton use, biologic therapy status, PRP formulation and injection technique, and follow-up plan up to 48 weeks.
Perianal Crohn's disease documentation specifics: Include indication, concomitant biologic therapy status, number of injections, and clinical/endoscopic outcome measures when available.
Documentation Required
Documentation Requirements
Prior authorization requests must include detailed clinical documentation to support use of becaplermin or PRP, tailored to the therapy: eligibility criteria for becaplermin and baseline wound and PRP technical details for PRP.
Required clinical documentation for becaplermin: transcutaneous partial pressure of oxygen (TcPO2) ≥ 30 mm Hg at ulcer margin or dorsum of foot (when indicated), ulcer staging (full-thickness stage III/IV), evidence of participation in a wound management program (sharp debridement, offloading/non-weight bearing, infection control), nutritional/laboratory labs for pressure ulcer candidates (albumin >2.5 g/dL, total lymphocyte count >1000/μL, normal vitamins A and C), and treatment plan including dosing and expected duration (typically once daily up to 20 weeks).
Required clinical documentation to support PRP use: baseline wound characteristics (etiology, size in cm2, depth, duration), prior standard therapies attempted or contraindications, offloading capability and plan (if applicable), exact PRP preparation method (device, single vs double spin), platelet concentration and volume per treatment, activation method, number and timing of treatments, concurrent/comparative therapies, and follow-up plan with objective healing measures and timepoints.
Prior authorization and detailed documentation requirement: Heterogeneous study methods and uncertain guideline recommendations justify detailed documentation to permit medical necessity review.
Denial Risk
Coverage, Step Therapy, and Denial Risks
Prior authorization reviewers will assess safety signals, step-therapy completion, and trial-like selection; inadequate or absent documentation, or use outside recommended indications, may result in denial.
Coverage stance that may trigger denial: PRP use for acute wounds, nonhealing chronic wounds outside evidence-based indications, miscellaneous non-orthopedic indications, or use of becaplermin outside specified candidate criteria may be considered investigational and denied.
Patient selection and offloading requirements: Document inability to offload when offloading was required by trial criteria; inability to offload may make a patient a poor candidate.
Step therapy: try standard wound care first / require standard care first: Require documentation that guideline-directed standard therapies (e.g., sharp debridement, offloading, infection control, appropriate dressings, compression for venous ulcers) were completed and failed or were contraindicated before advanced therapies are used.
Step-from standard wound care: Consideration of PRP generally in comparison to standard wound care; document attempts or inappropriateness.
Use after standard wound care: Recombinant PDGF generally considered after failure of standard wound care or as adjunct in patients meeting criteria.
For androgenetic alopecia: Require standard first-line therapies (e.g., topical minoxidil or oral finasteride when indicated) and document trial of guideline-recommended therapies first.
Denial Risk
Safety, Evidence, and Coding Risks
Safety signals (notably the increased cancer deaths with ≥3 tubes of Regranex) and variable evidence quality require careful review and may lead to authorization limits or denial.
Safety-related denial risk: Regranex (becaplermin) has an FDA black box warning after studies showing increased cancer deaths associated with use of 3 or more tubes; prior authorization may limit total quantity or require justification for recurrent/multiple-course use.
Documentation quality may affect coverage: Inadequate descriptions of procedures, PRP formulation, concentration/volume, offloading, concurrent wound care, or short follow-up limit the ability to assess medical necessity and may prompt denial.
Evidence limitations that may prompt denial: Small single-site RCTs, short duration of follow-up, inconsistent comparators, lack of patient-reported outcomes (QOL), and heterogenous PRP preparation methods can reduce confidence in benefit and may justify denial for unsupported indications.
Coding-related denial risk: Claims may be denied if providers do not use appropriate CPT/HCPCS/Revenue/ICD codes as required when reporting services.
Prior Authorization
Follow-up, Trial Documentation, and Coding
Follow-up and expected outcome documentation should mirror trial and guideline practice: objective wound measurements at defined intervals, infection and amputation surveillance, and longer-term follow-up when feasible to assess recurrence and safety.
Follow-up & evidence expectations: Typical follow-up for acute surgical or traumatic wounds would occur in months after starting treatment; for chronic wounds, document serial wound measurements, time to complete closure, infection status, and recurrence monitoring.
Trial-based documentation recommended: For indications with RCT evidence (e.g., certain diabetic foot ulcer trials), request documentation of the elements used in those trials (offloading, daily application frequency for becaplermin, duration up to typical trial lengths) to permit assessment of comparability.
Code usage for authorization: Providers must report exact CPT/HCPCS codes (e.g., 0232T, G0460, G0465, P9020, S0157, S9055) and ICD-10 diagnosis codes when requesting authorization or submitting claims.
Labeled indication
Treatment of lower‑extremity diabetic neuropathic ulcers extending into subcutaneous tissue as adjunct to good ulcer care
Platelet-rich plasma (PRP) — autologous blood product concentrated at point of care; systems vary
Product typeAutologous blood product concentrated at point of care to increase platelet and associated protein concentrations
Preparation variabilityMultiple FDA‑cleared 510(k) devices and procedures exist; platelet concentrations vary by system
DeliveryPrepared at point of care and applied topically or used as gel/injection depending on indication
Recombinant PDGF (becaplermin) — topically applied recombinant human PDGF studied as adjunctive therapy
ModalityTopically applied recombinant human platelet‑derived growth factor (becaplermin gel)
RoleStudied as an adjunctive therapy to standard wound care for diabetic lower‑extremity and pressure ulcers
Application contextUsed with sharp debridement, offloading/pressure relief, and infection control in trials
IntentDeliver concentrated growth factors directly into tissues to promote repair
Evidence statusInjection studies exist for hair, mucosal, perianal fistula, and other indications but are generally low quality or small
Platelet-rich plasma (PRP) — autologous blood product with high platelet concentration used to stimulate healing
Definition summaryPRP — autologous blood product with high platelet concentration used to stimulate healing and tissue regeneration
Preparation variabilityMethods vary (number of centrifugations, additives); no standardized protocol established
Clinical intentAttempt to enhance wound healing, graft incorporation, or tissue repair depending on indication
0232T CPT descriptor — Injection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed
0232T CPT descriptorInjection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed
UseApplies to PRP injections when billed under CPT 0232T
Coding noteInclude image guidance and preparation when performed per descriptor
G0460 / G0465 HCPCS descriptors — HCPCS descriptors for autologous platelet rich plasma or other blood-derived product for non-diabetic and diabetic wounds
G0460 descriptorAutologous platelet rich plasma or other blood‑derived product for non‑diabetic chronic wounds/ulcers, includes preparatory procedures and administration per treatment
G0465 descriptorAutologous platelet rich plasma for diabetic chronic wounds/ulcers using an FDA‑cleared device for this indication; includes preparatory procedures per treatment